Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Safety efficacy and tolerability of the calcitonin gene-related peptide monoclonal antibodies for migraine prevention treatment of migraine, Kuwait experience.
Headache
Headache Posters (7:00 AM-5:00 PM)
133

Migraine is prevalent in Kuwait and is associated with significant burdens. Calcitonin gene-related peptide (CGRP) monoclonal antibodies were approved as preventive treatment for episodic and chronic migraine.

We aimed to assess CGRP monoclonal antibodies efficacy and safety in Kuwait.

Migraine patients were identified in a tertiary center in Kuwait. The study included patients who received CGRP monoclonal antibodies. Patients were followed up every 4 weeks for at least 3 months. Primary end point was a 50% or greater reduction in migraine days. Secondary end points were change in the number of migraine days, number of days of use of analgesics, severity of headache pain, and change in Quality of life. Safety and tolerability were reported. Paired sample t test and Chi-square test were used to compare between different values.

This prospective study included 63 migraine patients, with a mean age of 44.59 years, disease duration of 21.87 years and treatment duration of 7.57 months. In their last visit, most of our sample showed improvement in quality of life (81%). Females represented 77.8% of the cohort. 57.2% of cohort used two or more previous prophylactic medication. 63.5% shifted to CGRP monoclonal antibodies because of lack of efficacy of previous medications and 20.6% because of adverse events. A 50% or greater reduction in the number of migraine days was achieved in 68.3% of patients. Patients had a significant reduction in migraine days, number of days of analgesic-usage and the severity of headache. Quality of life improved significantly. 14.4% reported adverse events. The most frequent ones were injection-site pain 6.4%, and constipation 6.4%. No Serious adverse events were reported.

Prophylactic CGRP monoclonal antibodies prevention of migraine were efficacious and reduced the number of monthly migraine days and the use of days of analgesics. It improved quality of life. It was tolerable and safe.

Authors/Disclosures
Hasan Ashkanani
PRESENTER
Hasan Ashkanani has nothing to disclose.
Jasem Yousef Al-Hashel, MD (IBN Sina Hospital, AlSabah Medical Area, Neurology Department) Dr. Al-Hashel has nothing to disclose.
Samar Farouk Ahmed, MD Dr. Ahmed has nothing to disclose.
Raed Alroughani, MD, FAAN Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, Bayer, Novartis, Merck, Roche, Sanofi. Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer, Biogen, Novartis, Merck, Roche, Sanofi.
Sawsan Alwazzan No disclosure on file